CeNeS Announces Termination of the Opiate Spray Agreements with Bioglan

31-Oct-2001
Cambridge, UK, October 30, 2001 - CeNeS Pharmaceuticals plc announced that it is terminating the development and licence agreements it has with Bioglan Pharma Plc for the development of a sub-lingual opiate spray product for the treatment of pain. CeNeS is reluctantly taking this action as a result of Bioglan's failure to comply with its development obligations under the agreement. CeNeS is currently seeking compensation from Bioglan for the losses it has suffered.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances